Data Shows Recession Fears May Be Overblown: Histogenics Corporation (HSGX)

H.C. Wainwright rated the Histogenics Corporation (NASDAQ:HSGX)’s stock as a Buy in a research note published on Monday, December 19th, 2016 and posted a $3.50 price target on the common stock of Histogenics Corporation (NASDAQ:HSGX). Other Wall Street experts have also recently posted reports on these shares. Needham gave the stock a Buy rating, while setting a price target at $8 in a research note from Monday, September 19th, 2016. Needham posted a $15 price target for Histogenics Corporation stock and rated the stock as a Buy in a research note dated Friday, November 13th, 2015.

At the moment, there are a total of 2 analysts who cover Histogenics Corporation (NASDAQ:HSGX) stock. Among that group, 1 of them gave BUY ratings, 0 of them rated the stock as OUTPERFORM, 1 recommended it as HOLD, 0 set the rating at UNDERPERFORM and 0 rated it as a SELL. Looking at the big picture from the data above, the average analyst rating for Histogenics Corporation is 2.00.

At times, the stock market can get highly confusing – even for some of the most experienced traders. Even when the result is what you had expected, the market might suddenly decide to make an opposing movement. This can spark a great deal of doubt and second-guessing. Keeping tabs on historical price performance, as well as both long-term and short-term trends, can be very useful. Over the past 7 days, Histogenics Corporation (NASDAQ:HSGX) stock has decreased in price by 27.68%. Looking backwards over the past quarter, these shares have fell -77.18%. Turning to look at the last 6 months, this stock has dropped 94.43% to its price. Since the beginning of the calendar year, this stock has moved down by 95.08%.

Now let’s examine some potential support and resistance levels for this particular stock. Following a recent spotcheck, the public organization Histogenics Corporation (NASDAQ:HSGX) has been observed as trading -78.19% away from its 90-day high price. Taking a look at the other side of things, this stock has been trading +60.00% away from its 90-day low. Moving to a broader perspective, this stock has recently been trading -96.18% away from its 52-week high and +60.00% away from its 52-week low price.

Regular shareholders want to find out how lucrative the capital that they’ve invested into a business has become. This particular public company has given a ROE of 66.40% . The lower the ROE, the worse a business is at generating profits. The Return on Assets (ROA) ratio, on the other hand, shows how profitable an organization is relative to its total assets owned. This company’s ROA is currently -73.30%. A percentage that’s positive means that profits exceed costs – so analysts consider the investment as a net gain. A negative result, however, indicates that costs outweigh profits – wo analysts would view it as a net loss.

Now let’s look at this public company’s trading volatility. Its 1-Week Volatility currently stands at 17.75%, while its Month Volatility is 16.13%. This stock’s ATR (Average True Range) is currently 0.03, and its beta factor is currently 2.64. Volatility demonstrates how much the stock will dive or rise if the wider market suffers or surges. A stock that has a beta score higher than 1 means that volatility is high, while less than 1 means that volatility is low.

Histogenics Corporation (NASDAQ:HSGX) stock slipped -$0.04 lower during the regular trading session on Saturday, hitting $0.13. This organization’s stock showed a trading volume of 34.87 million shares, compared to its average daily volume of 7.76M shares.